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Summary
Background The lipoprotein(a) pathway is a causal factor in coronary heart disease. We used a genetic approach to 
distinguish the relevance of two distinct components of this pathway, apolipoprotein(a) isoform size and circulating 
lipoprotein(a) concentration, to coronary heart disease.
Methods In this mendelian randomisation study, we measured lipoprotein(a) concentration and determined 
apolipoprotein(a) isoform size with a genetic method (kringle IV type 2 [KIV2] repeats in the LPA gene) and a 
serum-based electrophoretic assay in patients and controls (frequency matched for age and sex) from the Pakistan 
Risk of Myocardial Infarction Study (PROMIS). We calculated odds ratios (ORs) for myocardial infarction per 1-SD 
difference in either LPA KIV2 repeats or lipoprotein(a) concentration. In a genome-wide analysis of up to 
17 503 participants in PROMIS, we identified genetic variants associated with either apolipoprotein(a) isoform size 
or lipoprotein(a) concentration. Using a mendelian randomisation study design and genetic data on 60 801 patients 
with coronary heart disease and 123 504 controls from the CARDIoGRAMplusC4D consortium, we calculated ORs 
for myocardial infarction with variants that produced similar differences in either apolipoprotein(a) isoform size 
in serum or lipoprotein(a) concentration. Finally, we compared phenotypic versus genotypic ORs to estimate 
whether apolipoprotein(a) isoform size, lipoprotein(a) concentration, or both were causally associated with 
coronary heart disease.
Findings The PROMIS cohort included 9015 patients with acute myocardial infarction and 8629 matched controls. In 
participants for whom KIV2 repeat and lipoprotein(a) data were available, the OR for myocardial infarction was 0·93 
(95% CI 0·90–0·97; p<0·0001) per 1-SD increment in LPA KIV2 repeats after adjustment for lipoprotein(a) 
concentration and conventional lipid concentrations. The OR for myocardial infarction was 1·10 (1·05–1·14; 
p<0·0001) per 1-SD increment in lipoprotein(a) concentration, after adjustment for LPA KIV2 repeats and conventional 
lipids. Genome-wide analysis identified rs2457564 as a variant associated with smaller apolipoprotein(a) isoform size, 
but not lipoprotein(a) concentration, and rs3777392 as a variant associated with lipoprotein(a) concentration, but not 
apolipoprotein(a) isoform size. In 60 801 patients with coronary heart disease and 123 504 controls, OR for myocardial 
infarction was 0·96 (0·94–0·98; p<0·0001) per 1-SD increment in apolipoprotein(a) protein isoform size in serum 
due to rs2457564, which was directionally concordant with the OR observed in PROMIS for a similar change. The OR 
for myocardial infarction was 1·27 (1·07–1·50; p=0·007) per 1-SD increment in lipoprotein(a) concentration due to 
rs3777392, which was directionally concordant with the OR observed for a similar change in PROMIS.
Interpretation Human genetic data suggest that both smaller apolipoprotein(a) isoform size and increased 
lipoprotein(a) concentration are independent and causal risk factors for coronary heart disease. Lipoprotein(a)-
lowering interventions could be preferentially effective in reducing the risk of coronary heart disease in individuals 
with smaller apolipoprotein(a) isoforms.
Funding British Heart Foundation, US National Institutes of Health, Fogarty International Center, Wellcome Trust, 
UK Medical Research Council, UK National Institute for Health Research, and Pfizer.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license.
Introduction
Epidemiological studies and human genetic analyses 
have suggested that the lipoprotein(a) pathway is 
causally associated with coronary heart disease and 
aortic stenosis.1–5 Lipoprotein(a) is an LDL-like particle 
synthesised by the liver that consists of an 
apolipoprotein B100 molecule covalently linked to a 
very large glycoprotein known as apolipoprotein(a).6,7 
The striking heterogeneity in the size of 
apolipoprotein(a) in the general population (eg, 
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variation of up to ten times) is believed to be at least 
partly due to copy number variation in the LPA gene, 
which determines the number of repeats in the 
kringle IV type 2 (KIV2) protein domain present on 
apolipoprotein(a).7
Apolipoprotein(a) isoform size and lipoprotein(a) 
concentration are inversely correlated with each other, 
and have directionally opposite relationships with 
coronary heart disease risk.3 Findings from studies have 
generally showed lower relative risk for coronary heart 
disease in people with larger apolipoprotein(a) isoform 
size,3 and higher relative risk for coronary heart disease 
in people with higher lipoprotein(a) concentration.1,3 
Drugs have been developed to substantially reduce 
concentrations of lipoprotein(a).8,9 However, whether 
apolipoprotein(a) isoform size, soluble lipoprotein(a) 
concentration, or both are causally relevant to coronary 
heart disease is unknown.
Using the principle of mendelian randomisation, we 
did a series of human genetic and biomarker analyses to 
investigate the causal effects of apolipoprotein(a) isoform 
size and lipoprotein(a) concentration on the risk of 
coronary heart disease. We also measured oxidised 
phospholipids on apolipoprotein B-100 (OxPL-apoB) to 
investigate previous suggestions10 of a potential role of 
OxPL-apoB in mediating the association of lipoprotein(a) 
pathway in coronary heart disease.
Methods
Study overview
Our study had several inter-related components 
(figure 1). First, we calculated odds ratios (ORs) for 
myocardial infarction with measured values of LPA 
KIV2 repeats and with lipoprotein(a) con centration, 
adjusting them for each other. Second, to identify 
genetic variants exclusively associated with either 
apolipoprotein(a) protein isoform size or lipoprotein(a) 
concentration, we did genome-wide association 
analysis and investigated the likelihood of specificity of 
the genetic variants identified by analysing them in 
relation to established and emerging cardio vascular 
risk factors. Third, to test for causality, we compared 
ORs for coronary heart disease associated with either 
LPA KIV2 repeats or lipoprotein(a) con centration with 
similar differences produced by their trait-specific 
genetic variants. Fourth, we analysed soluble OxPL-
apoB concentrations in relation to genome-wide 
genotypes, including those relevant to apolipoprotein(a) 
isoform size or lipoprotein(a) con centration, to 
investigate the relevance of OxPL-apoB in mediating 
the association of lipoprotein(a) pathway in coronary 
heart disease risk.
The PROMIS study was approved by the Institutional 
Review Board at the Center for Non-Communicable 
Diseases (Karachi, Pakistan).
Research in context
Evidence before this study
We searched PubMed with the search terms “lipoprotein(a)”, 
“apolipoprotein(a) isoform protein size”, “coronary heart 
disease”, “mendelian randomisation”, and “oxidised 
phospholipids”, for observational or genetic epidemiological 
studies published in English before Jan 10, 2017, that had 
assessed lipoprotein(a) concentration, apolipoprotein(a) 
isoform size, measures of oxidised phospholipids, 
genome-wide genotypes, and clinical coronary heart disease 
outcomes in a common set of participants. Our search 
identified a few studies that had recorded combinations of 
some of the factors listed above. These studies reported results 
consistent with a causal role for the lipoprotein(a) pathway in 
coronary heart disease. However, we did not identify any 
studies that had concomitantly assessed all the relevant factors 
listed above in one population. Therefore, whether 
apolipoprotein(a) isoform size, soluble lipoprotein(a) 
concentration, or both, are causally associated with coronary 
heart disease is not known. Furthermore, whether oxidised 
phospholipids on apolipoprotein B100 are mediators of 
lipoprotein(a) pathways in coronary heart disease risk is 
unknown.
Added value of this study
The key distinctive feature of our study was its concomitant 
assessment of lipoprotein(a) concentration, apolipoprotein(a) 
isoform size (using complementary genotypic and phenotypic 
methods), oxidised phospholipids on apolipoprotein B-100, 
genome-wide genotypes, and confirmed first-onset myocardial 
infarction in over 15 000 patients and controls. We did 
integrative analyses by leveraging the principle of mendelian 
randomisation and supplemented our new data by accessing 
results from global genetics consortia of coronary heart disease 
and several cardiovascular traits.
Implications of all the available evidence
Our data have suggested three main findings. First, both smaller 
apolipoprotein(a) isoform size and elevated lipoprotein(a) 
concentration are independent and causal risk factors for 
coronary heart disease. Second, there are shallow and broadly 
continuous relationships (in opposite directions) of coronary 
heart disease risk with apolipoprotein(a) isoform size and with 
lipoprotein(a) concentration, even after these traits were 
adjusted for each other. Third, human genetic data support 
previous suggestions that oxidative damage could mediate the 
pathological effects of lipoprotein(a) on coronary heart disease. 
Our findings advance understanding of the causal relevance of 
the lipoprotein(a) pathway to coronary heart disease and 
suggest that interventions that lower lipoprotein(a) 
concentration could be more effective in reducing coronary heart 
disease risk in individuals who have smaller apolipoprotein(a) 
isoforms than individuals with larger isoforms.
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Participants
We assayed LPA KIV2 repeats, apolipoprotein(a) protein 
isoform size, lipoprotein(a) concentration, and genome-
wide genotypes in patients with acute myocardial 
infarction and frequency-matched controls in the 
Pakistan Risk of Myocardial Infarction Study (PROMIS),11 
a case-control study of patients with confirmed first-
onset acute myocardial infarction recruited from seven 
centres in five cities in Pakistan. Patients were eligible if 
they had a myocardial infarction and had characteristic 
symptoms of an event within 24 h of hospital admission, 
typical changes on electrocardiogram (ECG), and a 
positive troponin-I test. Controls were hospital visitors, 
concurrently identified in the same hospitals as patients 
with myocardial infarction, who did not have a self-
reported history of cardiovascular disease or ECG 
changes consistent with a previous myocardial infarction. 
Controls were matched to myocardial infarction cases by 
sex and age (5-year bands). Non-fasting blood samples 
(with the time since last meal and time since onset of 
chest symptoms recorded) were taken from each 
participant and centrifuged within 45 min of 
venepuncture. Serum samples collected with serum 
separating tubes were stored at –80°C. 
Based on sample availability, we selected a group of 
9015 cases and 8629 controls for assay of lipoprotein(a) 
concentration and lipid-related markers. We had 
sufficient assay resources to measure LPA KIV2 repeats 
in 6277 cases and 6387 controls, OxPL-apoB in 
8406 controls, and apolipoprotein(a) protein isoform size 
in 3987 controls. Data were available to the PROMIS 
investigators. Participants in PROMIS provided written 
informed consent. 
To investigate whether single nucleotide poly-
morphisms for either apolipoprotein(a) protein isoform 
size or lipoprotein(a) concentration were relevant to 
coronary heart disease and cardiovascular traits, we 
accessed results from the largest available genetic 
consortia of relevant outcomes and traits: 
CARDIoGRAMplusC4D consortium (60 801 coronary 
heart disease cases, 123 504 controls12), Global BPgen 
Consortium (134 433 participants with blood pressure 
values13), Global Lipids Genetics Consortium 
(188 577 participants with conventional lipid fractions14), 
Genetic Investigation of ANthropometric Traits 
(183 727 participants with anthropometric traits15), and 
Meta-Analyses of Glucose and Insulin-related traits 
Consortium (46 368 participants with glycaemic traits16).
Procedures
Technicians were not aware of the phenotypic status of 
the participants’ samples. We measured apolipoprotein(a) 
isoform size with complementary genotypic and 
phenotypic methods. We genotyped LPA KIV2 repeats in 
PROMIS participants with a validated quantitative real-
time polymerase chain reaction (qPCR) assay that 
measured copy number variation repeats in exon 4 of the 
LPA gene.4 We did a multiplex qPCR with probes for the 
KIV2 sequence with albumin as a control gene. Primers 
specific for the KIV2 sequence were used to amplify 
106 base pairs of exon 4 of the LPA coding sequence. All 
reactions were carried out in 96-well plates with each 
plate containing nine calibration controls with a known 
number of KIV2 repeats. The LPA KIV2 repeat for each 
sample was established by calculating the difference in 
cycle thresholds (ΔCT) between the KIV2 sequence and 
albumin probes. We assessed serum apolipoprotein(a) 
protein isoforms in a randomly selected subset of 
participants with electrophoresis and immunoblotting.17 
Apolipoprotein(a) isoform size was reported as the size 
of the major isoform with the highest density. The size of 
the major apolipoprotein(a) isoform measured with this 
method is directly proportional to the number of KIV2 
domains of the major isoform.17
We measured lipoprotein(a) concentration using 
methods insensitive to apolipoprotein(a) isoform size 
hetero geneity in two laboratories. We used a highly 
sensitive immunoturbidimetric assay (Denka Seiken, 
San Jose, CA, USA) in all PROMIS participants.18 We also 
assessed lipoprotein(a) concentration in a subset of 
participants with an in-house ELISA that used a 
monoclonal antibody against apolipoprotein(a), does not 
recognise the KIV2 domain and, hence, is independent 
of apolipoprotein(a) isoform size.
We measured OxPL-apoB using chemiluminescent 
ELISA as described previously.19 Briefly, monoclonal 
antibody MB47 was added to microtiter well plates to bind 
a saturating amount of apolipoprotein B100, plasma was 
added (1:50 dilution), and oxidised phospholipids detected 
Figure 1: Overview of analyses
Analysis 1: ORs for myocardial infarction with measured values of LPA KIV2 
repeats and lipoprotein(a) concentration, adjusted for each other. Analysis 2: 
Genome-wide association analyses of apolipoprotein(a) protein isoform size 
and lipoprotein(a) concentration and identification of variants that are 
exclusively associated with either apolipoprotein(a) protein isoform size or 
lipoprotein(a) concentration. Analysis 3: Test for causality by comparison of ORs 
for coronary heart disease associated with either LPA KIV2 repeats or 
lipoprotein(a) concentration with equivalent differences produced by their 
trait-specific genetic variants. Analysis 4: Study of soluble OxPL-apoB 
concentrations in relation to genome-wide genotypes. KIV2=kringle IV type 2. 
OR=odd ratio. OxPL-apoB=oxidised phospholipid on apolipoprotein B100. *Data 
only used in genetic analyses. †Data used in mendelian randomisation analyses.
Genetic
determinants 
 LPA KIV2 (6277 cases; 6387 controls) 
Apolipoprotein(a) protein
isoform size (3987 controls)*   
Lipoprotein(a) concentration
(9015 cases; 8629 controls) 
Coronary heart disease risk
CARDIoGRAMplusC4D 
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123 504  controls)†  
 OxPL-apoB
concentration
(6734 controls)  
2 
1 3 
4 
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with biotinylated murine monoclonal antibody E06. This 
measurement represents the immunoreactivity of 
monoclonal antibody E06 to OxPL-apoB containing-
lipoproteins and is not a direct chemical measure of 
oxidised phospholipids in plasma. The coefficients of 
variation for lipoprotein(a) concentration, apolipo-
protein(a) protein size, LPA KIV2 repeats, and OxPL-apoB 
concentration were all less than 5%. We also measured 
several additional soluble analytes (appendix pp 2–3).
We did genome-wide genotyping in 17 503 participants 
(9013 cases of myocardial infarction and 8490 controls from 
PROMIS) using high-density gene arrays (Illumina 
Human 650K and Omni express 770K; Illumina, San 
Diego, CA, USA). SNPs with departure from Hardy-
Weinberg equilibrium (p<0·0005), call rate of less than 
95%, or minor allele frequency of less than 1% were 
excluded from the analyses. Participants were omitted 
from the analysis if there was evidence of cryptic 
relatedness, inconsistency of self-reported and genetically 
defined sex, or if more than 5% of genotype data were 
missing. Measured genome-wide genotypes were imputed 
using the global 1000 Genomes reference panel (version 3),20 
yielding information on roughly 9 million variants.
Statistical analysis
To calculate risk of myocardial infarction for soluble 
lipoprotein(a) concentration or LPA KIV2 repeats, analysis 
was restricted to participants with complete data. We log-
transformed lipoprotein(a) concentrations. Analysis of the 
cross-sectional correlates of lipoprotein(a) traits was 
restricted to controls in PROMIS. We characterised 
associations of log-lipo protein(a) concentrations or LPA 
KIV2 repeats with other risk factors using linear regression 
analyses adjusted for age and sex and calculated partial 
correlation coefficients adjusted for age and sex. From 
each fitted regression model, we calculated overall 
adjusted mean values for log-lipoprotein(a) concentrations 
or KIV2 repeats within quintiles of continuous markers, 
or within each category for categorical variables as 
described previously.1 We calculated ORs for myocardial 
infarction per 1-SD differences in LPA KIV2 repeats or 
log-lipoprotein(a) concentration using unconditional 
logistic regression analyses, progressively adjusting for 
age, sex, self-reported ethnicity, recruitment centre, 
history of diabetes, waist-to-hip ratio, hypertension, and 
tobacco smoking. We adjusted ORs with LPA KIV2 
repeats for lipoprotein(a) concentration and vice versa. To 
characterise shapes of associations with myocardial 
infarction, ORs were calculated using quintiles or 
other predefined categories of exposure variables; 
corresponding 95% CIs were estimated as described 
previously.1 Effect modification was evaluated by fitting a 
multiplicative term to the model.
To identify genetic determinants of apolipoprotein(a) 
protein isoform size or lipoprotein(a) concentration in 
healthy controls in PROMIS, we used linear regression 
additive models adjusted for age, sex, and ten principal 
components. To control for population stratification, we 
Controls Patients
n/N (%) analysed Mean (SD) or n (%) n/N (%) analysed Mean (SD) or n (%)
LPA KIV2 repeats (ΔCT)* 6387/8629 (74%) 3·17 (0·49) 6277/9015 (70%) 3·14 (0·49)
Lipoprotein(a) concentration (nmol/L)† 8629/8629 (100%) 41·01 (48·60) 9015/9015 (100%) 48·91 (53·91)
Apolipoprotein(a) protein isoform size 
(KIV2 repeats)
3987/8629 (46%) 23·95 (5·64) ·· ··
Demographic and anthropometric markers
Age (years) 8629/8629 (100%) 54 (9) 9015/9015 (100%) 54 (11)
Men 8629/8629 (100%) 6817 (79%) 9015/9015 (100%) 7482 (83%)
Waist-to-hip ratio 8629/8629 (100%) 0·96 (0·20) 9015/9015 (100%) 0·97 (0·06)
Lipid-related markers
Total cholesterol concentration (mg/dL) 8629/8629 (100%) 181 (52) 9015/9015 (100%) 195 (52)
LDL-cholesterol concentration (mg/dL) 8629/8629 (100%) 110 (39) 9015/9015 (100%) 127 (44)
HDL-cholesterol concentration (mg/dL) 8629/8629 (100%) 35 (10) 9015/9015 (100%) 35 (10)
Triglyceride concentration (mg/dL)‡ 8629/8629 (100%) 183·16 (0·54) 9015/9015 (100%) 169·01 (0·56)
OxPL-apoB concentration (nM) 6734/8629 (78%) 7·3 (3·3) ·· ··
Medical history, blood pressure, and tobacco use
History of type 2 diabetes 8629/8629 (100%) 1210 (14%) 9015/9015 (100%) 1801 (20%)
History of hypertension 8629/8629 (100%) 2416 (28%) 9015/9015 (100%) 2881 (32%)
Systolic blood pressure (mm Hg) 8629/8629 (100%) 128 (10) 9015/9015 (100%) 130 (23)
Current tobacco users 8629/8629 (100%) 2591 (30%) 9015/9015 (100%) 4415 (49%)
KIV2=kringle IV type 2. OxPL-apoB= oxidised phospholipids on apolipoprotein B100. *LPA KIV2 repeat for each sample was established by calculating the difference in cycle 
thresholds (ΔCT) between the KIV2 sequence and albumin (control gene) probes. †Eight participants were found to have a lipoprotein(a) value of 0 and were omitted from 
the analyses. ‡Geometric mean.
Table: Participant characteristics in PROMIS
See Online for appendix
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used measured genome-wide variants to calculate 
principal components. The predominant apolipo-
protein(a) isoform size was used in the genetic analyses. 
We implemented step-wise conditional analyses to 
identify SNPs in dependently associated with apolipo-
protein(a) isoform size or lipoprotein(a) con centration. 
Each independent SNP was assessed for associations 
with a panel of soluble analytes (appendix pp 2–3). Our 
mendelian randomisation analyses involved both single-
variant and multiple-variant approaches.21 Pleiotropy was 
declared at a nominal p<0·01. Linkage dis equilibrium 
(LD) plots were visualised using directly genotyped SNPs 
in PROMIS. Analyses were done with Stata (version 10), 
R (version 3.3.2), HAPLOVIEW (version 4.2), IMPUTE-2 
(version 2), and SNPTEST-2 (version 2).
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. DS had access to all the data in the 
study and DS, DJR, and JD had final responsibility for 
the decision to submit for publication.
Figure 2: Association of variants specifically associated with apolipoprotein(a) isoform size and lipoprotein(a) concentration with various factors in PROMIS
Bars are 95% CIs. LPA=lipoprotein(a) gene. KIV2=kringle IV type 2. eGFR=estimated glomerular filtration rate. LpPLA2=lipoprotein-associated phospholipase A2. 
CFH=complement factor H. MDA-LDL=malondialdehyde-modified LDL. CXCL12=C-X-C motif chemokine 12. FGF21=fibroblast growth factor 21. ICAM=intercellular 
adhesion molecule 1. VCAM=vascular cell adhesion molecule. MMP9=matrix metallopeptidase 9. CRP=C-reactive protein. VEGF=vascular endothelial growth factor. 
RAGE=receptor for advanced glycation end products. NrCAM=neural cell adhesion molecule.
Apolipoprotein(a) protein isoform-serum
LPA KIV2 repeats
Log lipoprotein(a) (mg/dL) 
Oxidised phospholipids (ng/μL)
LDL-cholesterol (mg/dL)
HDL-cholesterol (mg/dL)
Log-triglycerides (mg/dL)
Systolic blood pressure (mm Hg)
Diastolic blood pressure (mm Hg)
Glucose (mg/dL)
HbA1c (%)
BMI (kg/m2)
eGFR (mL/min per 1·73 m2)
Heart rate
Waist-to-hip ratio
Cigarettes smoked per day
LDL-large (units)
LDL-medium (units)
LDL-small (units)
LDL-diameter (units)
HDL-large (units)
HDL-small (units)
VLDL-large (units)
VLDL-intermediate (units)
Apolipoprotein B (mg/dL)
Apolipoprotein A1 (mg/dL)
Apolipoprotein A2 (mg/dL)
Apolipoprotein C3 (mg/dL)
Apolipoprotein AV (mg/dL)
Apolipoprotein E (mg/dL)
Log LpPLA2 mass
LpPLA2 activity (nmol/min per mL)
CFH binding to MDA-LDL
CXCL12 (mg/dL)
FGF21 (mg/dL)
C-peptide (mg/dL)
Cystatin-C (ng/μL)
E-selectin (ng/mL)
P-selectin (ng/mL)
ICAM (ng/mL)
VCAM (ng/mL)
MMP9 (mg/dL)
Insulin (mU/L)
Log-CRP (mg/dL)
Factor-VII (ng/mL)
VEGF (ng/mL)
Interleukin 8 (ng/mL)
Interleukin 18 (ng/mL)
RAGE (ng/mL)
NrCAM (ng/mL)
3623
6734
16 832
16 700
17 165
11 864
11 831
16 485
10 627
7922
9913
16 934
8125
6283
7467
7467
7467
7467
7467
7467
7467
7467
12 071
12 067
11 994
11 986
10 579
12 082
10 986
11 995
6734
9017
9106
9634
4936
8302
5838
5785
5762
8501
8445
4544
3848
3848
3773
3848
3836
3658
N p value
SD change in trait per unit 
increase in the risk score 
2·8 × 10¹⁷
0·05
0·70
0·78
0·73
0·80
0·76
0·67
0·95
0·09
0·63
0·10
0·50
0·46
0·34
0·61
0·65
0·61
0·64
1·00
0·45
0·71
0·04
0·62
0·42
0·69
1·00
0·24
0·31
0·92
0·33
0·99
0·96
0·67
0·16
0·56
0·72
0·23
0·37
0·15
0·95
0·90
0·67
0·79
0·27
0·98
0·59
0·74
0·55
0–0·025 0·025 0·05 0·075 0·1
0·48
0·03
0·17
0·98
0·39
0·28
0·31
0·27
0·06
0·13
0·46
0·27
0·32
0·08
0·14
0·49
0·94
0·50
0·02
0·16
0·44
0·47
0·67
0·60
0·96
0·46
0·41
0·44
0·32
0·44
0·29
0·28
0·66
0·67
0·72
0·27
0·44
0·09
0·54
0·07
0·90
0·96
0·63
0·51
0·91
0·49
0·61
0·50
p value
5·2 × 10²⁷
0·14
0–0·1 0·1–0·25
SD change in trait per copy 
of the minor allele  
12 072
12 661 0·872·3 × 10⁵³
rs2457564      rs3777392
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Results
Baseline characteristics of the participants in PROMIS 
are summarised in the table. As would be expected, LPA 
KIV2 repeats were inversely associated with lipoprotein(a) 
concentration and OxPL-apoB in the control participants 
(appendix p 4). LPA KIV2 repeats and apolipoprotein(a) 
protein isoform size were significantly, but imperfectly, 
correlated (r=0·33, p<0·0001; appendix p 5) in the control 
group. Apolipoprotein(a) protein isoform size was more 
strongly related to lipoprotein(a) concentration and 
OxPL-apoB than were LPA KIV2 repeats in the control 
participants (appendix pp 4, 6). However, neither apolipo-
protein(a) protein isoform size nor LPA KIV2 repeats 
were strongly associated with the other cardio vascular 
traits we studied (appendix pp 4, 6). Lipoprotein(a) 
concentration was positively associated with LDL 
cholesterol, HDL cholesterol, and OxPL-apoB, and, 
inversely correlated with triglycerides (appendix p 7). As 
would be expected, there was a high degree of correlation 
(r=0·92, p<0·0001; appendix p 8) between lipoprotein(a) 
concentrations measured using two different assay 
methods, yielding similar genetic and other cross-
sectional correlates for each method (appendix p 9).
We found two SNPs, rs10455872 and rs3798220, which 
were previously reported as a genetic score for 
lipoprotein(a) concentration,2 to be associated with 
apolipoprotein(a) isoform size and LPA KIV2 repeat 
number (appendix p 10). By contrast, our objective was to 
identify genetic variants exclusively associated with 
either apolipoprotein(a) isoform size or log-lipoprotein(a) 
concentration, but not both. Our genome-wide 
association analyses identified 232 SNPs associated with 
apolipo protein(a) protein isoform size at p<5 × 10–⁸ 
(genome-wide significance threshold; appendix p 11), 
including eight SNPs shown to be independent from 
each other in step-wise conditional analyses (appendix 
p 12). Only rs2457564 was not related to lipoprotein(a) 
concentration or the other traits we measured (figure 2). 
Each copy of the minor allele at rs2457564 (minor allele 
frequency: 0·41) decreased apolipoprotein(a) protein 
isoform size by 0·24 SD units (p=5·20 × 10–²⁷). Allelic 
variation at rs2457564 was associated with LPA KIV2 
repeat number (β=0·15 SD units; p=2·3 × 10−⁵³; figure 2). 
The minor allele frequency of rs2457564 in PROMIS was 
similar to the minor allele frequencies observed for other 
global ethnicities (0·45) in the 1000 Genomes project.
We identified 324 SNPs associated with log-
lipoprotein(a) concentration at p<5 × 10−⁸ (appendix p 13), 
including 25 SNPs shown to be independent from the 
others in step-wise conditional analyses (appendix p 14). 
rs3777392 (minor allele frequency 0·09) located in the 
first LD block of LPA was associated with log-
lipoprotein(a) concentration, but not with apolipo-
protein(a) protein isoform size nor other cardiovascular 
and other traits we measured (figure 2).
The minor allele frequency of rs2457564 in PROMIS 
was similar to the minor allele frequencies observed for 
other global ethnicities (0·06) in the 1000 Genomes 
project. The two variants rs2457564 and rs3777392 were 
found to be in low LD (r²=0·05). rs2457564 or rs3777392 
were not convincingly associated with cardiometabolic 
risk factors analysed in previously published consortia 
based analyses (appendix p 15).
In PROMIS, associations of myocardial infarction risk 
with measured values of LPA KIV2 repeats and 
lipoprotein(a) con centration were weak and broadly 
continuous (figure 3). After adjustment for lipoprotein(a) 
Figure 3: Mutually adjusted association of LPA KIV2 repeats and lipoprotein(a) concentration with coronary 
heart disease in PROMIS
Bars are 95% CIs. (A) Association of LPA KIV2 repeats with coronary heart disease risk. (B) Association of 
lipoprotein(a) with coronary heart disease risk. KIV2=kringle IV type 2. OR=odds ratio.
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Figure 4: Phenotypic and genotypic assessment of apolipoprotein(a) isoform 
size and lipoprotein(a) concentration in coronary heart disease
(A) OR for coronary heart disease per 1-SD increment in LPA KIV2 repeats. (B) OR 
for coronary heart disease per 1-SD increment in lipoprotein(a) concentration. 
Phenotypic associations were computed in PROMIS and genetic associations 
were computed using data from the CARDIoGRAMplusC4D consortium. 
KIV2=kringle IV type 2. OR=odds ratio.
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concentration and several other cardiovascular risk 
factors, the OR for myocardial infarction was 0·93 
(95% CI 0·90–0·97; p<0·0001) per 1-SD increment in 
LPA KIV2 repeats. This finding was directionally 
concordant with the OR in CARDIoGRAMplusC4D for 
coronary heart disease of 0·96 (0·94–0·98; p<0·0001) per 
1-SD increment in apolipoprotein(a) isoform size due to 
rs2457564 (figure 4), and with the OR for coronary heart 
disease of 0·98 (0·98–0·99; p<0·0001; appendix p 12) 
with a genetic score consisting of the eight independent 
LPA KIV2 variants.
After adjustment for LPA KIV2 repeats and several 
other cardiovascular risk factors, the OR in PROMIS for 
myocardial infarction was 1·10 (95% CI 1·05–1·14; 
p<0·0001) per 1-SD increment in lipoprotein(a) 
concentration (appendix p 16). This finding was 
directionally concordant with results from 
CARDIoGRAMplusC4D; the OR for coronary heart 
disease of 1·27 (1·07–1·50; p=0·007) per 1-SD higher log-
lipoprotein(a) concentration due to rs3777392 (figure 4), 
and with the OR for coronary heart disease of 1·12 
(1·10–1·14; p<0·0001) with a genetic score comprising 
the 25 independent lipoprotein(a) variants. Associations 
of lipoprotein(a) concentration with coronary heart 
disease risk in PROMIS were similar across groups 
defined by different mean LPA KIV2 repeats (pinteraction=0·1; 
appendix p 17).
Among the randomly selected subset of 6734 healthy 
controls who had genome-wide genotypes and 
OxPL-apoB data from PROMIS, we observed genome-
wide significant associations of rs10455872, rs3798220, 
and other LPA gene variants with circulating OxPL-apoB 
(eg, p=4 × 10−¹³ for rs7770628, the lead variant in LPA; 
appendix p 18), but not variants at any other loci across 
the genome. The association of rs7770628 with OxPL-
apoB was not significant after adjustment for LPA KIV2 
repeats (or for log-lipoprotein[a] concentrations; figure 5), 
and the associations of OxPL-apoB with genetic variation 
at the LPA locus were no longer significant after analyses 
were conditioned on LPA KIV2 or log lipoprotein(a) 
concentration (appendix pp 18–19).
Discussion
Our large-scale integrative human genetic and biomarker 
study aimed to investigate the causal components of the 
lipoprotein(a) pathway that could increase coronary heart 
disease risk. Our mendelian randomisation analyses 
suggest that both small apolipoprotein(a) isoform size 
and increased lipoprotein(a) concentration are in-
dependent and causal risk factors for coronary heart 
disease. Both apolipoprotein(a) isoform size and lipo-
protein(a) concentration were associated with coronary 
heart disease risk, independent of conventional lipids. 
We found weak and broadly continuous relations (in 
opposite directions) between coronary heart disease risk 
and apolipoprotein(a) isoform size and lipoprotein(a) 
con centration, even after adjustment for each other. 
Further more, in a genome-wide analysis of OxPL-apoB 
concentration, we found that LPA variants are strongly 
associated with OxPL-apoB concentration, supporting 
previous suggestions that oxidative damage could 
mediate the pathological effects of lipoprotein(a) in 
coronary heart disease.10 Collectively, these findings 
advance under standing of the role of the lipoprotein(a) 
pathway in coronary heart disease and might have 
implications for the prevention of coronary heart disease.
Previous observational studies could not distinguish 
the effects of apolipoprotein(a) isoform size from 
lipoprotein(a) concentration on coronary heart disease 
because they did not measure both traits in the same 
participants in sufficiently large numbers. A previous 
gene-centric study found that two SNPs (rs3798220 and 
rs10455872), which together explain about one-third of 
the variation in lipoprotein(a) concentration, were 
robustly associated with coronary heart disease.2 However, 
because the SNPs were both located in the LPA gene and 
showed associations with both apolipoprotein(a) isoform 
size and lipoprotein(a) concentration, it was not possible 
to conclude which component of the lipoprotein(a) 
pathway was causally associated with coronary heart 
disease. Similar considerations applied to a mendelian 
randomi sation study4 that used another genetic tool, the 
LPA apo(a) isoform size-determining copy-number 
variant. By contrast, in our study we were able to 
distinguish the causal effects of apolipoprotein(a) isoform 
size from lipoprotein(a) concentration on coronary heart 
disease because we identified genetic variants associated 
with one of these traits but not with both.
Our study identified several variants at the LPA locus 
that were associated with OxPL-apoB concentration. We 
also showed that these genetic associations were 
Figure 5: Association of rs7770628 with OxPL-apoB after adjustment for KIV2 repeats and log-lipoprotein(a) 
concentration in PROMIS
Bars are 95% CIs. KIV2=kringle IV type 2. OxPL-apoB=oxidised phospholipid on apolipoprotein B100.
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dependent on apolipoprotein(a) isoform size or lipo-
protein(a) concentration, suggesting that oxidised 
phospholipids, apolipoprotein(a) isoform size, and 
lipoprotein(a) concentration are causally linked and 
located on the same pathway. Oxidised phospholipids are 
immunogenic, accumulate in atherosclerotic lesions, 
and mediate plaque destabilisation.22 Previous studies 
have reported that the oxidised phospholipids with 
lipoprotein(a) might modulate trafficking of monocytes 
during atherogenesis and might also mediate pro-
inflammatory activation of monocytes.23 Lipoprotein(a) 
and its associated oxidised phospholipids have been 
proposed to have multiple atherogenic effects, including 
proliferation of vascular smooth muscle cells and foam-
cell formation, which promote release of pro-
inflammatory mediators (eg, interleukin 8) and 
anti-fibrinolytic effects.22 Oxidised phospholipids and 
lipoprotein(a) could also mediate macrophage apoptosis 
by signalling through the CD36–Toll-like receptor 2 
pathway, generating reactive oxygen species dependent 
on NADPH oxidase.22 In view of our findings, elucidation 
of the exact mechanisms by which the lipoprotein(a) 
pathway exerts vascular effects by involving oxidised 
phospholipids should be a priority.
Our findings might have implications for emerging 
therapies that target lipoprotein(a) pathways, which, to 
date, have been hampered by poor understanding of the 
mechanisms by which this lipoprotein is formed and 
cleared.24 The LDL receptor does not seem to have a major 
role in lipoprotein(a) clearance, which could explain why 
statins are generally ineffective in the reduction of 
lipoprotein(a) concentration.25 However, mipomersen, 
which lowers LDL by inhibiting apolipoprotein B100 
synthesis, lowers lipoprotein(a) concentration by about 
25%.26 Monoclonal antibodies against proprotein 
convertase subtilisin/kexin type 9 (PCSK9) also lower 
lipoprotein(a) concentration by 20–35%,27 although the 
mechanism is unknown. Similarly, inhibitors of 
cholesteryl ester transfer protein, which have not yet been 
shown to reduce the risk of cardiovascular disease, can 
lower lipoprotein(a) concentration by 30–40%.28 By 
contrast, trials of apolipoprotein(a)-specific antisense 
oligonucleotide have reported up to 90% mean reductions 
in lipoprotein(a) concentration (and a proportional 
decrease in associated oxidised phospholipids) through 
inhibition of hepatic apolipoprotein(a) synthesis.8,9 
Because these reductions in lipoprotein(a) were achieved 
in individuals with both low and high baseline 
concentrations of lipoprotein(a) and were not 
accompanied by substantial changes in concentrations of 
other lipoproteins, such new agents could help test 
whether specific and substantial reductions in 
lipoprotein(a) concentration prevent cardiovascular 
disease outcomes. Our results imply that therapies that 
lower lipoprotein(a) concentrations might have greatest 
clinical effect in patients with small apolipoprotein(a) 
isoforms and high lipoprotein(a) concentration.
Our study has several strengths. It was unique in its 
combination of statistical power, detailed characterisation 
of the lipoprotein(a) pathway, and use of multiple assays to 
enhance validity. For example, in one group of participants, 
we assayed apolipoprotein(a) isoform size (with two 
different, but complementary, methods), lipoprotein(a) 
concentration (with two similar methods in two different 
laboratories), oxidised phospholipids, several established 
and emerging cardiovascular risk factors, and genome-
wide genotypes. Specifically, we made use of the advantages 
of both genotypic and phenotypic methods to measure 
apolipoprotein(a) isoform size; the genotypic methods 
afforded the scalability necessary for a genetic 
epidemiological study and the phenotypic methods 
ensured a high degree of biological specificity. Consistent 
with a previous study,29 we observed a modest correlation 
between the genotypic and phenotypic methods we used to 
measure apolipoprotein(a) isoform size, reflecting the 
inherent strengths and limitations of each approach. For 
example, whereas the genetic method (qPCR) cannot 
estimate the number of KIV2 repeats in an allele-specific 
manner, the phenotypic method (immunoblotting) 
provided information for each expressed allele. Conversely, 
the phenotypic method cannot differentiate between an 
individual who is a carrier of the null allele compared with 
individuals homozygous for an active allele.29 The 
frequency of the null allele has been reported to be 3% in a 
white European population.30
Our study also had some limitations. Patients in 
PROMIS, who tended to have early-onset myocardial 
infarction in urban Pakistan, could be unrepresentative of 
patients with coronary heart disease in other populations. 
However, we found that the results from genetic analysis 
of coronary heart disease in almost 18 000 participants in 
PROMIS were broadly similar to those observed in over 
180 000 participants in the global CARDIoGRAMplusC4D 
consortium, which included patients with coronary heart 
disease who were mostly of white European ancestry with 
diverse clinical characteristics. We could not directly 
investigate whether associations of LPA with lipoprotein(a) 
traits varied by ethnicity because the relevant lipoprotein(a) 
traits were not available from CARDIoGRAMplusC4D. 
PROMIS was not sufficiently powered to study 
phenotypically assessed apolipo protein(a) isoform size 
directly in relation to myocardial infarction because, due 
to reasons of cost and feasibility, apolipoprotein(a) isoform 
size was measured in only about one-fifth of PROMIS 
participants. For analyses that required extraction of data 
from external genetic consortia, we could not adjust 
associations between genotypes and coronary heart 
disease risk for potential mediators, nor analyse 
instrumental variables. In principle, the few genetic 
variants we found to be associated with apolipoprotein(a) 
isoform size or lipoprotein(a) con centration, but not both, 
could somehow be unrepresentative of lipoprotein(a) 
biology, but there is, as yet, no direct evidence to support 
or refute this theoretical possibility.
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We conclude that human genetic data suggest that both 
small apolipoprotein(a) isoform size and high 
lipoprotein(a) concentration are independent and causal 
risk factors for coronary heart disease. Interventions that 
lower lipoprotein(a) concentration could be more 
effective in reducing coronary heart disease risk in 
individuals who have small apolipoprotein(a) isoforms.
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